Improved testing of recent HIV-1 infections with the BioRad avidity assay compared to the limiting antigen avidity assay and BED Capture enzyme immunoassay: evaluation using reference sample panels from the German Seroconverter Cohort.

The overall FRRs (‘long-term infections’ plus ‘challenge specimen’) for BED-CEIA (14%), BioRad (4.4%) and LAg Avidity (3.7%) were significantly higher for BED-CEIA compared to BioRad ( p = 0.01) and LAg Avidity ( p = 0.005), but pairwise comparisons between tests for all subsets of ‘long-term infections’ ( Figure 1b ) and ‘challenge specimens’ ( Figure 2c ) did not reach statistical significance (all p >0.05).

also in 111,027 other papers